Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis.

Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J.

PLoS One. 2013 Jun 11;8(6):e65952. doi: 10.1371/journal.pone.0065952. Print 2013. Review.

2.

A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.

Wei W, Wu Q, Zhou J, Kong Y, You H.

Int J Environ Res Public Health. 2015 Aug 21;12(8):10039-55. doi: 10.3390/ijerph120810039.

3.

Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.

Dakin H, Fidler C, Harper C.

Value Health. 2010 Dec;13(8):934-45. doi: 10.1111/j.1524-4733.2010.00777.x. Epub 2010 Sep 3.

4.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
5.

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.

Xing T, Xu H, Cao L, Ye M.

PLoS One. 2017 Jan 20;12(1):e0169444. doi: 10.1371/journal.pone.0169444. eCollection 2017. Review.

6.

Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation.

Tsai WL, Sun WC, Cheng JS.

Int J Mol Sci. 2015 Nov 26;16(12):28126-45. doi: 10.3390/ijms161226087. Review.

7.

Kushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis.

Chen Z, Ma X, Zhao Y, Wang J, Zhang Y, Zhu Y, Wang L, Chen C, Wei S, Yang Z, Gong M, Shen H, Bai Z, Guo Y, Niu M, Xiao X.

Evid Based Complement Alternat Med. 2015;2015:529636. doi: 10.1155/2015/529636. Epub 2015 Aug 11. Review.

8.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

9.

Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients.

Wu Y, Jie Y, Li X, Huang M, Li X, Shi H, Chen S, Zhang M, Ao Y, Yang F, Gao Z, Lin G, Chong Y.

Clin Res Hepatol Gastroenterol. 2016 Apr;40(2):213-20. doi: 10.1016/j.clinre.2015.06.018. Epub 2015 Dec 1.

PMID:
26598028
10.

Entecavir versus lamivudine for the treatment of chronic hepatitis B: a systematic review.

Liang J, Tang YF, Wu FS, Deng X.

Pharmazie. 2012 Nov;67(11):883-90. Review.

PMID:
23210236
11.

Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.

Singal AK, Fontana RJ.

Aliment Pharmacol Ther. 2012 Mar;35(6):674-89. doi: 10.1111/j.1365-2036.2011.04990.x. Epub 2012 Jan 19.

12.

[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].

Yue W, Yuan H, Mao XR, Deng YD, Chen L.

Zhonghua Gan Zang Bing Za Zhi. 2013 Mar;21(3):184-8. Chinese.

PMID:
23967738
13.
14.

Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.

Wang X, Zhang C, Zhu Y, Xiong Y, Wang Y.

Antiviral Res. 2014 Mar;103:71-7. doi: 10.1016/j.antiviral.2014.01.009. Epub 2014 Jan 23.

PMID:
24462954
15.

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H.

Gastroenterology. 2007 Nov;133(5):1437-44. Epub 2007 Aug 14.

PMID:
17983800
16.

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.

Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N.

J Gastroenterol Hepatol. 2010 Jan;25(1):54-60. doi: 10.1111/j.1440-1746.2009.05952.x. Epub 2009 Sep 22.

PMID:
19780875
17.

The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis.

Yu S, Jianqin H, Wei W, Jianrong H, Yida Y, Jifang S, Liang Y, Zhi C, Hongyu J.

Ann Hepatol. 2013 May-Jun;12(3):364-72. Review.

18.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.

J Hepatol. 2012 Sep;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037. Epub 2012 May 30.

PMID:
22659518
19.

[Maternal-fetal outcomes of lamivudine treatment administered during late pregnancy to highly viremic mothers with HBeAg+ chronic hepatitis B].

Jiang HX, Han GR, Wang CM, Ji Y.

Zhonghua Gan Zang Bing Za Zhi. 2012 Dec;20(12):888-91. doi: 10.3760/cma.j.issn.1007-3418.2012.12.003. Chinese.

PMID:
23522247
20.

Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion.

Lau GK.

Liver Int. 2010 Apr;30(4):512-20. doi: 10.1111/j.1478-3231.2009.02198.x. Epub 2010 Jan 19. Review.

PMID:
20102511

Supplemental Content

Support Center